Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1826
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Rochester, MN
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within Mayo Clinic, Rochester, MN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1297–1308 of 1,826 matching trials with a site at Mayo Clinic, Rochester, MN.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Recruiting No phase listed Observational

A Registry for People With T-cell Lymphoma

NCT05978141
Status at this site: Not yet recruiting
Conditions
Adult T-cell Leukemia/Lymphoma, Aggressive NK-cell Leukemia, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T-cell Lymphoma, Breast Implant-Associated Anaplastic Large Cell Lymphoma, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Chronic Lymphoproliferative Disorder of NK Cells, Enteropathy-associated T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Follicular T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Mycosis Fungoides, NK-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Sezary Syndrome, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), T-cell Large Granular Lymphocytic Leukemia, T-cell Lymphoma, T-cell Prolymphocytic Leukemia
Interventions
Optional Blood Sample and Nail Sample
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
26
States / cities
Duarte, California • San Diego, California • San Francisco, California + 20 more
Active, not recruiting Phase 2 Interventional

Loncastuximab Tesirine in WM

NCT05190705
Site status not listed — check the official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
Dexamethasone, Loncastuximab Tesirine
Drug
Lead sponsor
Shayna Sarosiek, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Seattle, Washington
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Placebo, Taletrectinib
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more
Active, not recruiting Not applicable Interventional Results available

ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease

NCT03499964
Site status not listed — check the official record
Conditions
Urethral Stricture
Interventions
Control Treatment, Optilume Drug Coated Balloon (DCB)
Device
Lead sponsor
Urotronic Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Daytona Beach, Florida + 17 more
Conditions
Musculoskeletal Injury
Interventions
Electromagnetic transduction therapy (EMTT), Radial pressure waves, Shock wave
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Hormonal Gender-Affirming Therapy
Interventions
Plethysmography, Spirometry
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
14 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting No phase listed Observational Accepts healthy volunteers

Late Onset Alzheimer's Disease

NCT05010603
Status at this site: Recruiting
Conditions
Alzheimer Disease
Interventions
Blood Draw, Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
Genetic · Other
Lead sponsor
Columbia University
Other
Eligibility
55 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Miami, Florida • Aurora, Illinois + 9 more
Recruiting Phase 2Phase 3 Interventional

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

NCT03851445
Status at this site: Recruiting
Conditions
Previously Treated Non-Small Cell Lung Cancer
Interventions
Screening Platform
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1229
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 807 more
Active, not recruiting Phase 2 Interventional Results available

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

NCT03587740
Site status not listed — check the official record
Conditions
Breast Cancer
Interventions
T-DM1
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
60 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
14
States / cities
Duarte, California • Stamford, Connecticut • Boston, Massachusetts + 10 more
Conditions
Metastatic Solid Tumors, Stage 4 Cancer
Interventions
The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
Device
Lead sponsor
New Phase Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Active, not recruiting Phase 3 Interventional

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142
Site status not listed — check the official record
Conditions
Immunoglobulin A Nephropathy
Interventions
Placebo (matched to Povetacicept), Povetacicept
Drug
Lead sponsor
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
77
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Conditions
Advanced or Metastatic NSCLC
Interventions
Carboplatin, Cisplatin, Datopotamab deruxtecan, KEYTRUDA®
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.